Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 41-45

  Camacho, Raul C ^a   Zafian, Peter T ^a   Achanfuo Yeboah, Joana ^a   Manibusan, Anthony ^b   Berger, Joel P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMBRX INC   (United States)

Author keywords

Diabetes; FGF21; Hyperinsulinemic euglycemic clamp; Insulin resistance; Mouse

Indexed keywords

ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR 21; INSULIN; PEG30 Q108; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DIET; DIET RESTRICTION; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE UTILIZATION; HORMONE ACTION; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

DIABETES; FGF21; HYPERINSULINEMIC-EUGLYCEMIC CLAMP; INSULIN RESISTANCE; MOUSE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FIBROBLAST GROWTH FACTORS; INSULIN; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; RETINOL-BINDING PROTEINS, PLASMA; TIME FACTORS; TRIGLYCERIDES;

EID: 84885484874     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.023     Document Type: Article

References (37)

1. Adams, A.C., Cheng, C.C., Coskun, T., Kharitonenkov, A., 2012. FGF21 Requires betaklotho to Act In Vivo. PLoS One 7, e49977.
2. Ayala, J.E., Bracy, D.P., McGuinness, O.P., Wasserman, D.H., 2006. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55, 390-397. (Pubitemid 43343268)
3. Badman, M.K., Koester, A., Flier, J.S., Kharitonenkov, A., Maratos-Flier, E., 2009. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931-4940.
4. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437. (Pubitemid 46825495)
5. Basu, A., Basu, R., Shah, P., Vella, A., Johnson, C.M., Jensen, M., Nair, K.S., Schwenk, W.F., Rizza, R.A., 2001. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 50, 1351-1362. (Pubitemid 32500168)
6. Berglund, E.D., Li, C.Y., Bina, H.A., Lynes, S.E., Michael, M.D., Shanafelt, A.B., Kharitonenkov, A., Wasserman, D.H., 2009. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084-4093.
7. Cho, H., Daniel, T., Buechler, Y.J., Litzinger, D.C., Maio, Z., Putnam, A.M., Kraynov, V.S., Sim, B.C., Bussell, S., Javahishvili, T., Kaphle, S., Viramontes, G., Ong, M., Chu, S., Becky, G.C., Lieu, R., Knudsen, N., Castiglioni, P., Norman, T.C., Axelrod, D.W., Hoffman, A.R., Schultz, P.G., DiMarchi, R.D., Kimmel, B.E., 2011. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl. Acad. Sci. U S A 108, 9060-9065.
8. Consoli, A., 1992. Role of liver in pathophysiology of NIDDM. Diabetes Care 15, 430-441.
9. Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., Moller, D.E., Kharitonenkov, A., 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027.
10. Fisher, F.M., Estall, J.L., Adams, A.C., Antonellis, P.J., Bina, H.A., Flier, J.S., Kharitonenkov, A., Spiegelman, B.M., Maratos-Flier, E., 2011. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152, 2996-3004.
11. Hennige, A.M., Stefan, N., Kapp, K., Lehmann, R., Weigert, C., Beck, A., Moeschel, K., Mushack, J., Schleicher, E., Haring, H.U., 2006. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. Faseb J. 20, 1206-1208.
12. Huang, W., Dedousis, N., Bandi, A., Lopaschuk, G.D., O'Doherty, R.M., 2006. Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology 147, 1480-1487. (Pubitemid 43244383)
13. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., Elmquist, J.K., Gerard, R.D., Burgess, S.C., Hammer, R.E., Mangelsdorf, D.J., Kliewer, S.A., 2007. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425. (Pubitemid 46825496)
14. Iozzo, P., Hallsten, K., Oikonen, V., Virtanen, K.A., Kemppainen, J., Solin, O., Ferrannini, E., Knuuti, J., Nuutila, P., 2003. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. J. Clin. Endocrinol. Metab. 88, 2055-2060. (Pubitemid 36549877)
15. Ito, S., Kinoshita, S., Shiraishi, N., Nakagawa, S., Sekine, S., Fujimori, T., Nabeshima, Y. I., 2000. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98, 115-119.
16. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., Bright, S., Moyers, J.S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S.F., Knierman, M.D., Hale, J.E., Coskun, T., Shanafelt, A. B., 2008. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell Physiol. 215, 1-7. (Pubitemid 351363185)
17. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., Gromada, J., Brozinick, J.T., Hawkins, E.D., Wroblewski, V.J., Li, D.S., Mehrbod, F., Jaskunas, S.R., Shanafelt, A.B., 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635. (Pubitemid 40814671)
18. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., Hansen, B.C., Shanafelt, A.B., Etgen, G.J., 2007. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774-781. (Pubitemid 46143178)
19. Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., 2011. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624.
20. Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Dalla Man, C., Cobelli, C., Cline, G.W., Shulman, G.I., Waldhausl, W., Roden, M., 2004. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53, 3048-3056. (Pubitemid 39564478)
21. Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Rosenblatt, K.P., Kliewer, S.A., Kuro-o, M., 2007. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695. (Pubitemid 47501965)
22. Mashili, F.L., Austin, R.L., Deshmukh, A.S., Fritz, T., Caidahl, K., Bergdahl, K., and Zierath., J. R., Chibalin, A.V., Moller, D.E., Kharitonenkov, A., Krook, A., 2011. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab. Res. Rev. 27, 286-297.
23. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D., Kahn, B.B., 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343. (Pubitemid 34087557)
24. Mu, J., Pinkstaff, J., Li, Z., Skidmore, L., Li, N., Myler, H., Dallas-Yang, Q., Putnam, A.M., Yao, J., Bussell, S., Wu, M., Norman, T.C., Rodriguez, C.G., Kimmel, B., Metzger, J. M., Manibusan, A., Lee, D., Zaller, D.M., Zhang, B.B., Dimarchi, R.D., Berger, J.P., Axelrod, D.W., 2012. FGF21 Analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505-512.
25. Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Kuro-o, M., 2007. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104, 7432-7437. (Pubitemid 47185923)
26. Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B.N., Mangelsdorf, D.J., Kliewer, S.A., Burgess, S.C., 2009. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U S A 106, 10853-10858.
27. Rossetti, L., Massillon, D., Barzilai, N., Vuguin, P., Chen, W., Hawkins, M., Wu, J., Wang, J., 1997. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J. Biol. Chem. 272, 27758-27763. (Pubitemid 27473574)
28. Steele, R., Wall, J.S., De Bodo, R.C., Altszuler, N., 1956. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am. J. Physiol. 187, 15-24.
29. Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., Asada, M., Komi-Kuramochi, A., Oka, S., Imamura, T., 2008. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006-1014. (Pubitemid 351482834)
30. Torres, T.P., Fujimoto, Y., Donahue, E.P., Printz, R.L., Houseknecht, K.L., Treadway, J.L., Shiota, M., 2011. Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyper-insulinemia in zucker diabetic fatty rats. Diabetes 60, 2225-2233.
31. Veniant, M.M., Hale, C., Helmering, J., Chen, M.M., Stanislaus, S., Busby, J., Vonderfecht, S., Xu, J., Lloyd, D.J., 2012. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 7, e40164.
32. Wasserman, D.H., 2009. Four grams of glucose. Am. J. Physiol. Endocrinol Metab 296, E11-21.
33. Wu, A.L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., Kates, L., van Bruggen, N., Leabman, M., Wong, A., West, D., Stern, H., Luis, E., Kim, H.S., Yansura, D., Peterson, A.S., Filvaroff, E., Wu, Y., Sonoda, J., 2011. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl Med. 3113ra126.
34. Wu, M., 2011. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U S A 108, 5378-5383.
35. Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., Chen, J.L., Jung, D.Y., Zhang, Z., Ko, H.J., Kim, J.K., Veniant, M.M., 2009a. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259.
36. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y.Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.C., Graham, M., Busby, J., Hecht, R., Li, Y.S., Li, Y., Lindberg, R., Veniant, M.M., 2009b. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297, E1105-1114.
37. Zhang, X., Ibrahimi, O.A., Olsen, S.K., Umemori, H., Mohammadi, M., Ornitz, D.M., 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694-15700. (Pubitemid 43848456).